Shares in the U.S. generic drugmaker Mylan will begin trading on the Tel Aviv Stock Exchange Wednesday, the TASE said Monday. The move comes after Mylan last week won an Israeli court ruling rejecting Perrigo’s attempt to block Mylan from listing on TASE.
Dive Brief:
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
- In early April, Pennsylvania-based generic and specialty drug manufacturer Mylan made a $29 billion bid to purchase Ireland-based Perrigo. Perrigo has rejected the deal many, many times.
- Now, Mylan is taking the offer directly to shareholders. The proposal is: For each share of Perrigo, Mylan will offer $75 in cash, and 2.3 Mylan shares per Perrigo share.
- Once Mylan is listed on the Tel Aviv stock exchange, Perrigo shareholders in Israel will be able to vote on the buyout offer. This will increase the likelihood that Mylan will get enough votes to go through with the deal.
- Perrigo was trying to prevent Mylan’s listing on the exchange, arguing that the company likely won’t offer lasting value to investors since it may ditch the exchange several years after completing a Perrigo buyout (if it goes through). But an Israeli court denied Perrigo’s petition, ruling Mylan can list on the bourse.
